Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Inozyme Pharma, Inc. (INZY) had Debt to Capital Ratio of 0.39 for the most recently reported fiscal quarter, ending 2025-03-31.
Income Statement Financials | |
-- |
|
$-28.04M |
|
-- |
|
-- |
|
$27.69M |
|
$-27.69M |
|
$-0.35M |
|
$-28.04M |
|
$-28.04M |
|
$-28.04M |
|
$-28.04M |
|
$-28.04M |
|
$-28.04M |
|
$-27.69M |
|
$-28.20M |
|
64.28M |
|
64.28M |
|
$-0.44 |
|
$-0.44 |
|
Balance Sheet Financials | |
$93.64M |
|
$0.61M |
|
$1.53M |
|
$95.16M |
|
$42.78M |
|
$20.59M |
|
$20.59M |
|
$63.37M |
|
$31.80M |
|
$31.80M |
|
$31.80M |
|
64.47M |
|
Cash Flow Statement Financials | |
$-29.15M |
|
$33.68M |
|
$0.23M |
|
$21.39M |
|
$26.16M |
|
$4.76M |
|
$1.86M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
2.19 |
|
-- |
|
-- |
|
Debt to Capital Ratio |
0.39 |
1.46 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-29.15M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-88.18% |
|
-88.18% |
|
-29.46% |
|
-53.53% |
|
$0.49 |
|
$-0.45 |
|
$-0.45 |